<DOC>
	<DOCNO>NCT02643589</DOCNO>
	<brief_summary>The purpose study compare incidence GVHD haploidentical hematopoietic stem cell transplant recipient receive different dose antithymocyte globulin ( ATG ) acute graft-versus-host disease ( aGVHD ) prophylaxis . The investigator ' first objective investigate optimal dose ATG aGVHD .</brief_summary>
	<brief_title>Dose Study Antithymocyteglobulin Haploidentical Allogeneic Stem Cell Transplantation</brief_title>
	<detailed_description>Graft-versus-host disease ( GVHD ) remain major cause morbility mortality allogeneic hematopoietic stem cell transplantation ( HSCT ) graft HLA-mismatched family donor . Antithymocyteglobulin ( ATG ) widely use prevent acute GVHD ( aGVHD ) haploidentical HSCT . Notwithstanding , immunosuppressive effect ATG , may also increase risk opportunistic infection , necessitates use low possible dose . Till , optimal dose ATG known . Here , investigator compare outcome patient receive haploidentical HSCT treat two different dos ATG .</detailed_description>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<criteria>Haploidentical hematopoietic stem cell transplant recipient Subjects ( legally acceptable representative ) must sign informed consent document indicate understand purpose procedure require study willing participate study Any abnormality vital sign ( e.g. , heart rate , respiratory rate , blood pressure ) Patients condition suitable trial ( investigator ' decision )</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>haploidentical hematopoietic Stem Cell Transplantation Antithymocyte globulin</keyword>
	<keyword>acute graft-versus-host disease</keyword>
	<keyword>antithymocyte globulin</keyword>
</DOC>